Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases

Zealand Pharma and Generate will combine Zealand Pharma’s metabolic-health expertise with Generate’s proprietary generative AI platform to develop multispecific drug candidates with tailored biological functions. The announcement describes a collaboration and development objective, without reporting candidate results or financial terms.